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New Zealand has among the top two highest prevalence of cannabis 
use in the world. Additionally, the strains of cannabis on offer in the market 
of New Zealand is among the most potent ones available. With these two 
factors at play within New Zealand society, it is important to know the effects 
of cannabis on mental health. Studies have suggested that regular/heavy 
use of cannabis can lead to psychosis, however other studies have 
presented findings contrary to this. Studies consistently found that 
individuals with psychosis performed much poorer on working memory 
measure via the digit-symbol subset of the WAIS. Thus this study aimed to 
investigate how cannabis use may relate with performance on digit-symbol 
task and sub-clinical psychotic experiences. 
Method: A quantitative design was used to investigate relationships:  
between cannabis use, digit-symbol performance, and ratings of the Sub-
Psychotic Subjective Experiences Scale (SPSES). Fifty one convenience 
sample participants (n=51) were included in the results of the study. 69% 
were aged 18-24 years, 84% of the sample population were students, and 
majority Europeans. Males and females were equally represented. The 
research sessions were conducted in an office-type laboratory environment. 
The first part entailed participants completing Wechsler Abbreviated Scale 
of Intelligence 2nd edition (WASI-II), and Wechsler Adult Intelligence Scale 
3rd edition (WAIS-III) digit-symbol subtest with the researcher on a desk. 
Participants then moved to the computer to complete the questionnaires on 
background and history, cannabis use (Cannabis Use Problem 
Identification Test (CUPIT) and Cannabis Abuse Screening Test (CAST) 
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questionnaires for cannabis users), and the Sub-Psychotic Subjective 
Experiences (SPSES) questionnaire. 
Results: Participants were apportioned into four cannabis use groups using 
self-rating measures obtained from CUPIT and CAST scores. The user 
groups were 1: non-users, 2: previous users, 3: non-regular users, and 4: 
regular users. 
An overall  one-way (4 cannabis use groups) MANOVA conducted on the 
outcome variables digit-symbol scores, and SPSES scores, with  
depression scores and IQ scores as covariates) revealed no significant 
main effects, significant interactions or any significant covariates. 
Subsequent Spearman’s Rank-Order coefficient, however, indicated 
significant correlations of cannabis use with CUPIT scores, CAST scores, 
and use of other recreational drugs. Pearson’s correlation coefficient was 
used for correlation analyses for all other ratio and interval variables. There 
were no significant Pearson’s correlations found. 
Conclusion: The study found no significant association between regular 
cannabis use and digit-symbol performance; nor was there a significant 
association between cannabis use and sub-psychotic subjective 
experiences ratings. Therefore, the student-majority sample did not present 
any significant deficits in cognitive function depending on cannabis use. 





I wish to extend sincere gratitude to all my supervisors throughout 
my Research process, they include: Dr Jo Thakker, Dr Robert Isler, Dr 
Rebecca Sargisson, and Dr Jamie Veale. It has been a huge honour and a 
privilege to work with a team of such highly esteemed representatives from 
the school of Psychology. 
 
Thank you to the University of Waikato School of Psychology staff at large 
for providing me with the necessities. 
Throughout the period of my research, my family often wondered whether 
they still had a relative in New Zealand, and whether I was still surviving. 
Your patience, motivation, and differing forms of encouragement are 
extremely appreciated. To my wonderful parents (extended), I am forever 
grateful for your support and provision, and I wish to dedicate this thesis to 
you, your parents, and their grandchildren (my cousins). 
 
I would like to thank my church families here in New Zealand for all the 
support and encouragement throughout my research process. 
I wish to extend a special shout out to all those who volunteered to 
participate in my research, and a big thank you to Chawa & Taolo, Lisa, 





Table of Contents 
Abstract ....................................................................................................... i 
Acknowledgements .................................................................................... iii 
List of Tables............................................................................................. vii 
List of Figures .......................................................................................... viii 
List of Appendices ...................................................................................... ix 
List of Tests................................................................................................ x 
Introduction ................................................................................................ 1 
Literature Review ....................................................................................... 4 
1. Cannabis Use................................................................................... 4 
1.1. Prevalence ................................................................................. 4 
1.2. Types of cannabis and potency ................................................. 5 
1.3. Synthetic cannabis .................................................................... 6 
2. Implications of Cannabis Use ........................................................... 7 
3. Effects of Cannabis .......................................................................... 8 
3.1. Defining psychosis........................................................................ 8 
3.2. Cannabis and psychosis ............................................................. 10 
3.3. Cognitive effects of cannabis use ............................................... 12 
3.4. Chemical properties.................................................................... 13 
4. Digit-Symbol Task and Psychosis .................................................. 16 
5. Effect of Depression on Cognitive Function ................................... 18 
Purpose of this study ............................................................................ 18 
Method ..................................................................................................... 20 
1. Participants .................................................................................... 20 
2. Materials ........................................................................................ 22 
v 
 
2.1. Scoring ....................................................................................... 25 
3. Procedure ...................................................................................... 26 
4. Statistical Analysis ......................................................................... 28 
Results ..................................................................................................... 32 
1. Descriptive summary of Results of Variables ................................. 32 
1.1. Sub-Psychotic Subjective Experiences Scale (SPSES) Scores
 32 
1.2. WASI-II FSIQ-2 Scores ........................................................... 32 
1.3. Digit-Symbol Coding Test Scores ............................................ 33 
1.4. Cannabis use ........................................................................... 34 
1.1. Other Possible Confounds ....................................................... 39 
2. Correlations .................................................................................... 39 
2.1. Other Possible Confounds ....................................................... 40 
3. Multivariate Analysis of Covariance (MANCOVA) .......................... 40 
Discussion ............................................................................................... 42 
1. Cannabis Use................................................................................. 42 
2. SPSES findings .............................................................................. 43 
3. Depression ..................................................................................... 45 
4. IQ ................................................................................................... 45 
5. Digit-symbol ................................................................................... 47 
6. Limitations and further directions ................................................... 49 
6.1 Sample ........................................................................................ 49 
6.2 Materials ...................................................................................... 50 
vi 
 
Conclusion ............................................................................................... 54 
References............................................................................................... 56 
Appendices .............................................................................................. 64 
Appendix A: Research Participant Recruitment Advertisement ............ 64 
Appendix B: Participant Information Sheet ........................................... 65 
Appendix C: Participant Consent Form ................................................. 66 
Appendix D: Online Questionnaire Demographics ............................... 67 
Appendix E: Online Cannabis Use Problems Identification Test (CUPIT)
 ............................................................................................................. 69 
Appendix F: Cannabis Use Problems Identification Test (CUPIT) Scoring 
Information ............................................................................................ 73 
Appendix G: Cannabis Abuse Screening Tests (CAST) ....................... 74 
Appendix H: CAST scoring Information ................................................ 75 
Appendix I: Sub-Psychotic Subjective Experiences Scale (SPSES) .... 76 





List of Tables 
Table 1. Participant Demographic information summary ......................... 21 
Table 2. Overall descriptive statistics for relevant variables ..................... 34 
Table 3. Types of Cannabis used in the different groups ......................... 35 
Table 4. Bivariate correlations of cannabis use indicators ....................... 36 
Table 5. Descriptive statistics for variables in separate groups ............... 37 
Table 6. Other possible confounding variables in study ........................... 39 
























List of Figures 
Figure 1. Cannabis use on overall SPSES and digit-symbol scores ........ 38 







List of Appendices 
Appendix A: Research Participant Recruitment Advertisement ............... 64 
Appendix B: Participant Information Sheet .............................................. 65 
Appendix C: Participant Consent Form .................................................... 66 
Appendix D: Online Questionnaire Demographics ................................... 67 
Appendix E: Online Cannabis Use Problems Identification Test (CUPIT) 69 
Appendix F: Cannabis Use Problems Identification Test (CUPIT) Scoring 
Information ............................................................................................... 73 
Appendix G: Cannabis Abuse Screening Tests (CAST) .......................... 74 
Appendix H: CAST scoring Information ................................................... 75 
Appendix I: Sub-Psychotic Subjective Experiences Scale (SPSES) ........ 76 




List of Tests 
1. Wechsler Abbreviated Scale of Intelligence 2nd Edition (WASI-II)- 
Wechsler (2011) 
2. Wechsler Adult Intelligence Scale 3rd Edition (WASI-III): Digit-Symbol 
Subtest- Wechsler (1997) 
3. Sub-Psychotic Subjective Experiences Scale (SPSES)- Chiappelli, 
Nugent, Thangavelu, and Hong (n.d.)  
4. Cannabis Use Problem Identification Test (CUPIT)- Bashford, Flett, 
and Copeland (2010) 




New Zealand is ranking among the top two countries in the world with 
the highest cannabis use. The cannabis used in New Zealand has a 
stronger potency than traditional cannabis; in fact some of the strongest 
strains are grown and used here (United Nations Office on Drugs and Crime, 
2012). 
There exists a debate in the literature about the occurrence of psychosis as 
a result of heavy cannabis use.  This debate has been ongoing for decades, 
and though both ends of the argument present convincing evidence 
supporting their claims, there seems to be no conclusive study which 
successfully explains the underlying activity. Though the current study does 
not aim to uncover the underlying activity, the findings may be useful to 
further support either claim. 
Some literature suggests that heavy cannabis use may lead to the 
occurrence of psychosis (Andreasson, Allebeck, Engstrom, & Rydberg, 
1987; Myles, Myles, & Large, 2016) , whereas some literature suggests that 
cannabis use is in fact helpful in the treatment of psychosis (Ferraro et al., 
2013; Murray & Di Forti, 2016). On the other hand, some literature asserts 
that cannabis use under certain specified conditions is more likely to lead to 
psychosis; whilst claiming that use beyond the scope of these conditions 
should not lead to psychosis. Though the cause and effect relationship 
between cannabis use and occurrence of psychosis is unclear, there is a 
consistency in the correlation between cannabis use and first episode 
psychosis within the literature (Myles et al., 2016). 
2 
 
Furthermore, there is a consistent correlation within the literature between 
psychosis and performance on the Wechsler Adult Intelligence Scale (WAIS) 
digit-symbol subtest, revealing patients with psychosis (particularly 
schizophrenia) performing worse than the control groups in the varying 
studies. The digit-symbol test is usually used to measure working memory 
and processing speed. Hence inferior performance on this measure would 
imply impairment in the individual’s working memory and/or processing 
speed (Dickinson, Ramsey, & Gold, 2007).  
Patients with psychosis have been affirmed in numerous literature to have 
inferior working memory competences compared to their ‘healthy’ controls. 
These studies along with other relevant literature illuminating the topic of 
debate will be further outlined in the subsequent review of literature section. 
The aims of this study were: 1) to identify whether regular cannabis users 
in a general population may exhibit higher ratings of underlying sub-
psychotic experiences which may go undetected; 2) to assess whether 
cannabis use had an effect on working memory and processing speed using 
the digit-symbol subtest from the Wechsler Adult Intelligence Scale (WAIS); 
and 3) to evaluate the relationships between these three variables to detect 
any significant associations if any. 
With an existing relationship established in the literature between psychosis 
and performance on the digit-symbol test, this study aims to investigate how 
cannabis use would correlate with digit-symbol performance. There was 
only one study found which reported on this relationship (Jockers-Scherübl 
et al., 2007). These researchers used paired samples of a control ‘healthy’ 
group compared with a group of patients diagnosed with schizophrenia. This 
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entailed selected sampling with researcher manipulation over the study 
sample. 
The current study of this report used a convenience sample in the university 
environment to demonstrate a more natural representation of a general 
population. This study will also be focusing on measures of different 
variables compared to the one study that was found.  
The association between cannabis use and psychosis in the literature has 
not been very consistent, and for the current study it will be relevant to 
measure how cannabis use from a general population impacts subjective 
experiences.  
This topic will be relevant to the literature as it gives fresh insight on 
something that has been marginally explored, within a different setting and 
under different dynamics. This should help fill a gap in the literature on the 





1. Cannabis Use 
For centuries, humans have used cannabis for fibre, seed, seed oils, 
medical treatment, and recreationally (Davis, 2016). Di Marzo (2014) 
asserts that it is used in at least four fundamental dimensions of human life: 
religion, health, manufacture, and recreation. Medical Marijuana is used for 
the treatment of chronic pain, muscle spasms, anorexia, nausea, and sleep 
disturbances. In the 1830’s, Irish physician William O’Shaughnessy is 
alleged to have introduced the use of cannabis in a therapeutic setting in 
the western society (Di Marzo, 2014). The “explosion” of marijuana abuse 
arose in the 1960’s within the western world (Di Marzo, 2014).  
1.1. Prevalence   
The most widely used illicit drug among the global adult population (15-64 
years of age) is cannabis; with a worldwide prevalence ranging between 
about 2.6-5.0 per cent annually (UNODC, 2012). The highest prevalence of 
cannabis use in 2010 was reported in Oceania (primarily in New Zealand 
and Australia) ranging between 9.1-14.6 per cent (UNODC, 2012). The 
prevalence of cannabis use is much higher in New Zealand than the 
worldwide average. In New Zealand, approximately 42 per cent of all adults 
(15+ years) have tried using cannabis (Woodbridge, 2015). This was 
reported by the Ministry of Health (Manatu Hauora) in their New Zealand 
Health Survey in which they found that 11% of the participant adults 
reported using cannabis within the last 12 months. One out of every seven 
male participants in the survey had reported cannabis use within the last 12 
months. Of all the participants who reported cannabis use, one third (1 out 
of 3) reported using cannabis at least weekly. These statistics are 
5 
 
comparable to those of the United Nations in their report asserting that the 
international drug problem trends mostly among young males living in urban 
areas (UNODC, 2012). People who were unemployed and also people from 
disadvantaged backgrounds were reported to be more likely to use illicit 
drugs (UNODC, 2012). In New Zealand, adults living in the most deprived 
regions and Māori adults were more likely to report cannabis use in the last 
twelve months in the national Health survey (Woodbridge, 2015).  
1.2. Types of cannabis and potency 
The Cannabis herb is called Marijuana whilst the resin of Cannabis is called 
Hashish. Marijuana is the flower bud of the plant, and it contains the highest 
concentration of the psychoactive substance –Tetrahydrocannabinol (THC) 
within the plant. When the resin glands of the plant are compressed it is 
referred to as Hashish. In New Zealand, most seizure cases were 
predominantly caused by  cannabis herb (Marijuana) as opposed to Hashish 
(UNODC, 2012). Traditionally, Hashish has been known to have far greater 
levels of THC than Marijuana, thus was considered more problematic than 
Marijuana. The THC content of hashish was traditionally between 2-10 per 
cent, and that of Marijuana traditionally 0.5-9 per cent. Only about 0.5 of 
cannabis products were in the liquid form, and these would contain a higher 
potency. Cannabis oil contained about 10-30 per cent THC content, and 
Hashish oil about 40 per cent, and these both emerged in the 70’s (UNODC, 
2012). Though these liquid forms of cannabis are rarely used, the high 
potency of the THC content in them is noteworthy when looking into the 
impacts of cannabis use. 
There are notable increases over the past two decades in the cultivation of 
higher THC-content cannabis varieties in most  countries in Oceania and 
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other regions (UNODC, 2012). These variations of the drug are achieved 
through plant breeding and/or hydroponic farming. This means that New 
Zealand is ranking among the top two countries with the highest cannabis 
use, and the cannabis used has a stronger potency than traditional cannabis, 
in fact some of the strongest strains are grown and used here. The United 
Nations Office on Drugs and Crime (UNODC, 2012) also stated that 
augmented indoor production of cannabis is usually related to an increase 
in the potency of cannabis produced. The analyses of THC levels of 
samples confiscated in the United States indicated that THC content had 
more than doubled since the 1980’s, and the UNODC asserted that this 
entailed that in western countries, Marijuana is no longer ‘less problematic’ 
than Hashish. They also suggested that the local production of this high-
potency cannabis in large markets lead to imported cannabis becoming less 
significant within the market. 
1.3. Synthetic cannabis 
In New Zealand there have been increasing reports of synthetic cannabis 
available in the market, which would highly impact the dynamic of cannabis 
use (Satherly, 2017; Strongman, 2017). These strains of cannabis are made 
of different chemical compounds, and would result in different 
neurochemical activity. It is also worthy to note that synthetic cannabis has 
been found to be the cause of some deaths, whereas there are no reports 
of death resulting from natural cannabis (Satherly, 2017). New Zealand 
police have issued warnings about the synthetic strains of cannabis which 
are lethal. These strains of cannabis lack the natural controlling agents 
which moderate the effect of THC, thus resulting in unusually higher potency. 
The potency can reach up to fifty times the effect of natural THC, with the 
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average synthetic marijuana ranging between five to ten times THC potency 
(Satherly, 2017). Satherly (2017) stated that synthetic cannabis products 
were currently one of the easiest drugs to find on the streets. The New 
Zealand Herald reported that people seem to be able to distinguish the 
difference between the natural cannabis and the synthetic strains 
(Strongman, 2017). The synthetic cannabis was reported to be cheaper and 
have a distinctive smell unlike that of natural cannabis, and usually called 
by a different name “inert” (Strongman, 2017). This type of variant string of 
cannabis would possibly influence the validity, outcome, and confounding 
factors of this present study. The main reason for this would be that 
inauthentic strains would react differently on a neurochemical level than 
natural cannabis (Satherly, 2017). 
2. Implications of Cannabis Use 
The UNODC assert that cannabis use can cause serious impairment 
to one’s driving, and chronic use of cannabis can result in drug dependency, 
and behavioural and psychological problems, such as internalizing disorder 
(e.g., anxiety and depression). In New Zealand, 8 per cent of cannabis users 
participating in the national survey reported mental health harms, on 
account of their use of cannabis within the past 12 months. This is a 
relatively small percentage reported to call for serious attention on mental 
health issues arising from cannabis use on the basis of the ministry’s survey. 
However, this is not to rule out that regular/heavy cannabis users may 
experience mental health problems that they have not associated with their 
cannabis use, or are unable to identify, or are not reported. 
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3. Effects of Cannabis 
In a clinical experiment conducted by J. J. Moreau the 1840s in which 
participants (including himself) were administered hashish, the participants 
experienced “occurrences of delirium or of actual madness”. On the other 
hand, modern day users had varying reports on their experiences (Di Marzo, 
2014). Modern day clinical research on cannabis is conducted with precise 
doses of active compounds, whereas prior to the mid-1960’s the chemical 
basis of cannabis used in the research was not well established. 
3.1. Defining psychosis 
The New Zealand Early Intervention in Psychosis Society (NZEIPS) Inc. 
describes psychosis as a range of unusual experiences that can affect a 
person’s thoughts, feelings and experiences. The experiences can result in 
the person having difficulty in separating reality from non-reality. The New 
Zealand Mental Health Commission (MHC (1999)) explain that psychosis is 
a syndrome that features in a number of mental health disorders. This 
syndrome is recognized as a primary disturbance in perception 
(hallucinations), disturbed beliefs and interpretations of environment 
(delusions) and incoherent speech patterns (thought disorder). A ‘psychotic 
episode’ is when a person experiences this to the extent that it disrupts their 
ability to concentrate and maintain life responsibilities (Turner, Nightingale, 
Smith-Hamel, & Mulder, 2004).  
The Mental Health Commission (1999) identify three stages of early 




Non-specific changes in behaviour and mental state usually occur 
prior to the onset of the disorder. They may occur a few days or to 
an extended number of years prior to the onset with the following key 
features of this prodromal state: 
a. Sleep disturbances 
b. Appetite disturbance 
c. Notable unusual behaviour 
d. Blunted feelings or feelings incongruent to others 
e. Incoherent speech (difficult to follow) 
f. Notable preoccupation with unusual ideas 
g. Ideas of reference- things having special meaning 
h. Persistent feelings of unreality 
i. Changes in the way things appear, sound, or smell  
2) Acute phase 
Symptoms of hallucinations, delusions, and/or thought disorder fully 
develop, often in combination with other psychiatric symptoms (e.g., 
anxiety, depression). Other conditions may be present with the 
psychosis. 
3) Recovery phase 
Symptoms of the acute phase are reduced/ absent, usually following 
treatment of the acute phase. Following the psychotic episode, 
people may experience some difficulty returning to ‘normal’ and 
making sense of their experience. 
When investigating the subjective experiences of psychosis, McCarthy-
Jones, Marriott, Knowles, Rowse, and Thompson (2013) compiled a meta-
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synthesis of qualitative studies investigating the experience and highlighted 
four central themes: 
1. Losing- loss of consensual reality, loss of self, loss of hope and 
motivation, loss of security in body and world, loss of relationships 
and pain caused 
2. Identifying a need for, and seeking help 
3. Rebuilding and reforging- reality and self, hope and fighting back, 
security in body and world, relationships and recovering through 
them 
4. Better than new: gifts from Psychosis- reconnection with increased 
compassion for others, increased sense of creativity, individuals 
finding a sense of benefit from their experiences and giving back to 
others in similar situations. 
 
Fergusson, Poulton, Smith, and Boden (2006) stated that psychosis is 
measured using either diagnostic criteria for psychotic conditions, or using 
scales which rank the level of psychotic symptoms from severe to none. 
3.2. Cannabis and psychosis 
Over the past three decades, confounding evidence is continuously 
presented regarding the association between cannabis use and occurrence 
of Psychosis. In 1987, Andreasson et al. revealed a positive correlation 
between the onset of schizophrenia (a common psychotic disorder) and 
cannabis use through a 15 year follow-up study of 45 570 Swedish 
participants (Andreasson et al., 1987). Myles et al. (2016) research 
indicated that cannabis use is prevalent with first episode psychosis (FEP) 
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and schizophrenia, and their research did not illuminate a clear reason 
behind this association. Their meta-analysis along with the findings from the 
Dunedin longitudinal study (Fergusson et al., 2006) suggest that persistent 
cannabis use from early adolescence is strongly correlated with the 
development of psychosis and lower IQ later in adulthood.  Murray and Di 
Forti (2016) affirmed four other studies which further evidenced Andreasson 
et al. (1987) notion of a strong correlation between cannabis use and the 
occurrence of schizophrenia. 
Previous research from the 90’s has suggested that cannabis use could 
induce Psychosis, and literature from the early 90’s discusses “Cannabis 
Psychosis” (Ghodse, 1986; Hall, 1998; Imade & Ebie, 1991; McGuire et al., 
1994). Meanwhile, research from the early 2000’s to date has suggested 
that cannabis use closely correlates with schizotypy and schizophrenia 
(Barkus, Stirling, Hopkins, & Lewis, 2006; Degenhardt & Hall, 2002; Forti & 
Murray, 2005; Jockers-Scherübl et al., 2007; Murray & Di Forti, 2016). This 
indicates that research has shifted from a psychosis caused by cannabis 
use, to cannabis use not being a cause of psychosis, although psychosis 
occurring as a by-product. Though the evidence may be confounding and 
has evolved over the decades, the assumption that cannabis use is strongly 
correlated with psychotic experiences still stands. According to the DSM-5 
(p482) Cannabis is associated with psychotic disorders. 
Andreasson et al. (1987) are mentioned as the first researchers to suggest 
that cannabis use may cause schizophrenia. They conducted a study in 
which they aimed to evaluate the role of cannabis as a causal factor, with 
the consideration of some confounding factors. They acquired information 
about their study population regarding drug habits, psychiatric history and 
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social background from a national survey in Sweden. Andreasson et al. 
(1987) mention a Swiss study by Ruppen et al. (1973) in which these 
researchers found that heavy cannabis users reported higher estimates of 
their cannabis use in anonymous questionnaires as opposed to 
questionnaires that were not anonymous (such as the national survey used 
by Andreasson et al. (1987)). This suggests that it is likely that the 
estimations of cannabis use in their study were lower than actual 
consumptions levels. Above this proposed misestimating of cannabis use 
within the study cohort, the researchers were not able to ascertain whether 
the relationship was that of a cause as opposed to effect. Though they 
proclaim a statistical association, it is not distinct whether the cannabis use 
is the cause of the development of schizophrenia, or whether the 
development of schizophrenia caused the use of cannabis.  
Andreasson et al. (1987) conclude that cannabis use can only be 
considered a small indicator to the aetiology of schizophrenia. Only a 
minority of the schizophrenia cases in their study were cannabis users, with 
only 21 of them being heavy users out of 274 schizophrenia cases. To 
further support how discrepant this association is, Murray and Di Forti (2016) 
asserted that although there was a steep incline in the use of cannabis 
entering the latter part of the 20th century, there was no corresponding 
drastic incline in the onset of schizophrenia. 
3.3. Cognitive effects of cannabis use 
The “explosion” of marijuana abuse in the 1960’s brought up major efforts 
to identify chemical properties underlying the psychotropic activity. Di Marzo 
(2014) asserts that several of the first studies investigating the underlying 
mechanism of cannabis were prompted to corroborate the harmfulness of 
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cannabis as opposed to its medicinal properties. He alleges that this 
potential bias has influenced cannabinoid research, to an extent, for many 
decades. Di Marzo (2014) operated a laboratory, involved in cannabis and 
endogenous cannabinoids research, for 50 years. Hence, for at least five 
decades he was a professional in this realm, and would have been well 
acquainted with works specializing in the topic. Institute of Medicine, 
Benson, and Watson (1999) also allege that in controversial topics, scientific 
information is commonly misinterpreted, misrepresented, and over 
interpreted. According to them this includes the medical marijuana debate. 
3.4. Chemical properties 
Cannabis contains above 400 chemicals, and over 113 cannabinoids in 
Cannabis are unknown (Baggott, Coyle, Erowid, Erowid, & Robertson, 
2011). “Cannabinoid” is the description of the chemical constituents of the 
cannabis plant believed to have a common molecular structure. This 
structure is thought to be characteristic of the cannabis plant, or a derivative 
of it (Kalant, 2014). The most potent and studied psychoactive chemical in 
Cannabis is Tetrahydrocannabinol (THC). 
The endogenous (internal) cannabinoid system (ECS) modulates 
neuroactivity by playing important roles in the development of the central 
nervous system, synaptic plasticity, and response to internal (endogenous) 
and environmental insults (Lu & Mackie, 2016). This system is made up of 
cannabinoid receptors, endogenous cannabinoids, and enzymes 
responsible for the degradation and synthesis of endogenous cannabinoids. 
Disruptions of the Endocannabinoid System play a role in several 
psychiatric disorders such as schizophrenia.  
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On the other hand, the psychoactive chemical of cannabis, THC, is an 
exogenous (external) cannabinoid which produces biological effects 
through its interactions with the cannabinoid receptors. Di Marzo (2014) 
isolated numerous cannabinoids in cannabis over 50 years and found that 
no other cannabinoids showed the activity resembling that of from THC, 
thus bringing him and his team to conclude that there were no other major 
active compounds other than THC in the Hashish they sampled. Although 
over the years dozens of new cannabinoids have been found in various 
cannabis strain, with none presenting ‘marijuana-like’ activity, and most of 
them being minor constituents. 
 Outdated as their research may be, it is of relevance to note that  
Andreasson et al. (1987) reported Cannabis to have properties that are 
anticholinergic (inhibiting the action of Acetylcholine). Acetylcholine is 
primarily responsible for the stimulation of muscles; and also plays a major 
role with sensory neurons in scheduling REM (dream) sleep. Inhibition of 
this chemical would impair muscle stimulation, and regular sleep patterns. 
These researchers asserted that THC has strong negative effects on 
memory, cognition, and other functions of the central nervous system. 
Dickinson et al. (2007) aimed to further specify, and measure the magnitude 
of impairment of schizophrenia patients on the coding task in comparison to 
impairments on other traditional neuropsychological instruments. They 
conducted a meta-analysis of 40 articles that investigated the performance 
of schizophrenia patients on coding tasks and other cognitive measures 
which represented a minimum of two other domains of cognition. They were 
able to conclude that the digit-symbol task exposed an inefficiency in 
processing information, a central feature of schizophrenia cognitive deficit. 
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These findings coincide with those of Mohamed, Paulsen, O'Leary, Arndt, 
and Andreasen (1999), Leeson et al. (2008) and Pantelis et al. (1997). 
 
Contrary to all these findings, Ferraro et al. (2013) cited three meta-
analyses in their article which indicated that patients with psychosis using 
cannabis presented superior performance than patients with psychosis not 
using cannabis. Jockers-Scherübl et al. (2007) compared 39 patients with 
schizophrenia against 39 “healthy” controls on cognitive function with the 
effect of chronic cannabis use after 28 and more days of abstinence. Within 
the Schizophrenia group were 19 cannabis abusers and 20 non-abusers. 
The ‘healthy’ control comprised of 18 cannabis-abusers and 21 non-abusers. 
As supported by the findings in the previously mentioned studies, they found 
that the schizophrenia group performed poorer on the neuropsychological 
tests compared to the control group. They found that regular cannabis use 
deteriorated test performance in healthy controls, however regular users 
among the schizophrenia group improved cognition on some tests. They 
summarised that cannabis abuse had different effect on the patients with 
schizophrenia than the control group based on their cognitive function 
(Jockers-Scherübl et al., 2007). 
Jockers-Scherübl et al. (2007) found a statistically significant interaction 
between chronic cannabis use and the diagnostic group in their 
performance on the digit-symbol substitution test. Chronic abuse in the 
‘healthy’ controls reduced their performance on the digit-symbol test. 
Conversely, chronic cannabis use within the schizophrenia group seemed 
to significantly improve digit-symbol performance. This interaction was not 
so significantly present in the other applied cognitive tests they used. 
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However, patients with schizophrenia abusing cannabis generally still 
performed worse than cannabis abusing controls on most of the tests. 
4. Digit-Symbol Task and Psychosis 
Pantelis et al. (1997) assessed spatial working memory and planning 
abilities in 36 hospitalized patients with chronic Schizophrenia using a 
computerized Neuropsychological Test Automated Battery (CANTAB). 
They compared their performance with a control ‘normal’ group, and other 
patients with other neurological disorders. They found that the chronic 
Schizophrenia group displayed the most impairment in their performance in 
visuospatial memory span than any of the other groups. This group were 
least skilful in developing systematic strategy to complete the task, thus 
indicating that they relied on a limited visuospatial memory span. Pantelis 
et al. (1997) found that this group’s higher planning level on the CANTAB 
“Tower of London” task was lower too, as they made fewer perfect solutions 
and more moves to achieve completion of the task, and significantly slower 
movement than the other groups.  
The researchers deduced that the slowness indicated sensorimotor 
impairment. They concluded that the ‘initial thinking (planning)’ stages of the 
Schizophrenia group was not impaired, and their lowered performance 
compared to other groups resulted from significantly prolonged ‘subsequent 
thinking (execution)’ delays. 
Manoach (2003) cited 5 different neuroimaging studies that evidenced 
prefrontal cortex dysfunction in schizophrenia during working memory 
performance. The neuroimaging revealed ‘task-related hypofrontality’ in the 
schizophrenia patients. They demonstrated relative physiological hypo 
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activity in the prefrontal cortex during performance compared with the 
‘healthy subjects’. These findings of hypofrontality during working memory 
activation have been consistent even with widely varied methods, patient’s 
status and tasks used for activation. 
Leeson et al. (2008) found that patients with recent-onset psychosis 
performed significantly worse on the digit-symbol processing speed subtest 
along with other measures of verbal and working memory. This affirmed the 
finding of Manoach (2003) regarding hypofrontality during working memory 
activation in schizophrenia patients. In their study Leeson et al. (2008) 
paired 53 psychosis patients with 53 controls to compare their performance 
on all scales of measure include in the Wechsler Adult Intelligence Scale 
(WAIS). They aimed to distinguish whether poorer performance of the 
psychosis group was a generalized deficit, or whether there were underlying 
specific abnormalities. The two groups were matched according to age, sex, 
and current full-scale IQ scores. On all subtests, except the digit-symbol test, 
the groups presented similar patterns of performance. Performance results 
on this subtest accentuated a specific deficit within the psychosis group 
compared to their matched ‘healthy’ controls. 
 
The findings of Leeson et al. (2008) were further corroborated by the 
findings of Mohamed et al. (1999). Their study confirmed an inferior 
performance of schizophrenia patients on the digit-symbol test and 
comprehension subscale. Furthermore, the results of their study suggested 
that the impairment was characteristic of Schizophrenia. This was revealed 
through the fact that regardless of patient treatment, institutionalization, and 
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varying levels of chronic illness of the patients with schizophrenia, they 
consistently appeared to perform lower on these measures. 
5. Effect of Depression on Cognitive Function 
 
During the search for relevant literature, numerous articles came up on the 
impact of depression and bipolar on digit-symbol performance and cognitive 
function in general. These disorders were found to have an overlap in 
symptomatology presenting psychomotor deficiency (van Hoof, Jogems-
Kosterman, Sabbe, Zitman, & Hulstijn, 1998). Depression groups were 
found to perform poorer than their controls on the digit-symbol test (Hart, 
Kwentus, Wade, & Hamer, 1987; van Hoof et al., 1998). 
For this reason, depression was included within the measures as a likely 
confounding factor. This factor was projected to possibly impact the results 
in an unprecedented way. 
Purpose of this study 
The primary aim of this study was to explore relationships between 
cannabis use, subjective experiences, and performance on the digit-symbol 
subtest. The hypothesis supported by findings in the literature was that 
regular cannabis use would likely result in some occurrence of psychosis, 
at least on a sub-clinical level. The assumption was that regular cannabis 
use would also result in inferior performance on the digit-symbol task, 
indicating impaired working memory and processing speed. Therefore the 
hypothesis of the study was that regular cannabis use would result in a 
positive relationship with sub-psychotic subjective experiences (perception) 
ratings, and a negative relationship with digit symbol performance. 
Measurements of psychotic experiences was intentionally on a sub-clinical 
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level. Though the above literature mostly outlined findings including patients 
with schizophrenia, this study aimed to investigate the presence of sub-
clinical experiences of schizophrenia in regular cannabis users within a 
generalized setting. 
The next section outlines the methodology of this study along with the 
research process, and a plan of the statistical analyses further conducted 







This was a quantitative study primarily investigating one outcome 
variable (digit-symbol performance) and two predictor variables (cannabis 
use, and sub-psychotic subjective experiences). An investigation of the 
effect of cannabis use on sub-psychotic experiences was also a primary 
component of investigation.   
Two measures were used for cannabis use: one was measuring extent of 
cannabis use in participants having used cannabis (CUPIT scores); and the 
other categorizing cannabis use, categorising cannabis use in to four groups. 
Using IBM SPSS, Sub-psychotic subjective experiences scale (SPSES) 
scores were analysed as ordinal variables, digit-symbol scores as scale 
measures, CUPIT scores were taken as scale measures, and cannabis use 
was a nominal measure. Participants were only tested once and on a 
voluntary basis. 
1. Participants 
A non-selected sample of individuals were collected primarily through 
the university. Posters (see Appendix A), ‘word-of-mouth’, and social media 
advertising was used to gather participants for the study. Posters were 
placed around the Psychology department, and distributed via the 
psychology students’ mailing list. Participants within the Psychology 
department at the university were offered 1% course credit for any of the 
eligible course offering credit for research participation. As a result, majority 
of the participants were tertiary level students and from the University of 
Waikato where the study was conducted. 
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One pilot was tested in order to trial and redefine the procedure, and provide 
feedback and suggestions on the experience, and measure how long the 
process would take. 
A total of 52 participants (excluding the pilot) (n=52) were recruited for the 
study with an equal distribution between males (n=26) and females (n=26). 
Majority (n=36) of the participants fell into the age range of 18-24 years, and 
majority of them (n=44) were students. Table 1 below outlines 
demographics of the sample population. 
Table 1.  














































The first questionnaire collecting background information and 
demographics of the participant was devised by the researcher after finding 
relevant items in the literature found to negatively impact digit-symbol 
performance (e.g., mental health conditions, and use of other drugs). The 
questions were devised to take potential confounds into account, and gather 
information ordinarily used for demographics to outline a profile of the 
sample population. 
The Wechsler Abbreviated Scale of Intelligence second edition (WASI-II; 
Wechsler (2011)) was used to assess cognitive ability by producing an 
intelligence quotient (IQ). The main purpose of testing for IQ, was to 
eliminate further confounds in the research. It is an abbreviated version of 
the Wechsler Adult Scale of Intelligence (WAIS). This test was designed to 
quickly and accurately estimate cognitive intelligence when the full battery 
(the WAIS) is not feasible or necessary (McCrimmon & Smith, 2012). The 
WASI has been evidenced to be appropriate for clinical and research use 
(McCrimmon & Smith, 2012). In this case it was neither necessary nor 
feasible to administer the full battery, because only an estimate of cognitive 
ability was needed. This was to ensure that cognitive ability would not be 
the reason for poor scores.  
The scale offers two options for administration, one consisting of two 
subtests (FSIQ-2), and the other using all four subtests of the scale (FSIQ-
4). The FSIQ-2 was sued for this study. The two subtests administered were 
the Vocabulary and Matrix Reasoning tests, and these were sufficient to 
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estimate the participant’s Full Scale IQ range using a 95% confidence 
interval (McCrimmon & Smith, 2012; Wechsler, 2011). 
The digit-symbol substitution test was obtained from the third edition of the 
Wechsler Adult Scale of Intelligence (WASI-III). This subtest is a 
neuropsychological test often used to measure processing speed, working 
memory, and visuo-spatial skills (Bettcher, Libon, Kaplan, Swenson, & 
Penney, 2011). This test is done on paper using a pencil, and the participant 
is timed by the administrator. The participant is required to correctly fill in a 
series of symbols matching the number assigned to the symbol. They are 
presented with a template (see Appendix J) in which they have to fill in the 
empty boxes with matching symbols for the number above the empty box. 
The participant is given 90 seconds to fill in as many boxes as the can. This 
test is required to be administered in a quiet place, with minimal distraction, 
and on a table (Bettcher et al., 2011). 
 
The rest of the measures were completed electronically by the participant 
on their own with the researcher present for any further assistance or 
queries. These included cannabis use screening items, and a scale rating 
sub-psychotic experiences. 
The Cannabis Use Problems Identification Test (CUPIT) (see Appendix F) 
is a self-reporting screening scale comprised of 16 questions to detect 
current and potentially problematic use of cannabis (Bashford et al., 2010). 
This assessment battery includes a number of established measures of 
cannabis-related pathology from DSM-IV/ ICD-10 diagnostic criterion for 
cannabis use disorder. Bashford et al. (2010) found the CUPIT to be a 
reliable and valid battery appropriate for use within varying diverse 
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communities and for all ages. The CUPIT is readily available and can be 
self-administered by any individual wanting to use it. 
The Cannabis Abuse Screening Test (CAST) (see Appendix G) consists of 
six questions aimed at identifying patterns of cannabis use leading to 
negative consequences in an individual’s life on a social and/or health level 
(Legleye, Piontek, & Kraus, 2011a). (Legleye, Piontek, & Kraus, 2011b) 
confirmed that the CAST is appropriate for use in both clinical and research 
settings. They asserted that it is a useful scale to estimate Cannabis Use 
Disorder (CUD) prevalence. 
In order to measure subjective experiences with sub-psychotic elements, as 
highlighted in the section ‘Defining Psychosis’ from the literature review, a 
questionnaire was required to obtain a quantitative measure. There was no 
single scale obtainable that measures sub-clinical psychosis on its own. The 
literature suggested that psychosis could be detected in an interview. 
However, the purpose of measuring psychosis in the study was not 
diagnostic, it was merely to asses and compare subjective cognitive 
experiences between the groups. This measurement was used to examine 
the implicit notion that cannabis users would rank higher on the experiences 
scale compared to non-users. This was used to further investigate the 
presence of sub-clinical psychosis in regular cannabis users. 
The Sub-Psychotic Subjective Experiences Scale (SPSES) was used to 
assess how individuals would rank subjective experiences linked closely 
with psychosis in terms of frequency and intensity of experiences. Chiappelli 
et al. (n.d.) developed the SPSES which is made up of 21 five-point Likert 
scale items. The scale evaluates subjective cognitive experiences and was 
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developed after reviewing several interview-based rating measures on 
basic symptoms. Majority of the items are based on the ‘Cognitive 
Disturbance’ risk criteria from the “Schizophrenia Proneness Instrument, 
Adult version (SPI-A)”(Schultze-Lutter, Addington, & Rurhmann, 2007) 
ordinarily used in the field of medicine (psychiatry). The other items in the 
scale were adopted from other schizotypal personality assessment tools. It 
is a “self-rating under clinical interview environment” format. This entails that 
it should be administered in the presence of the interviewer, however, to be 
completed by the participant on their own. 
2.1. Scoring 
2.1.1. WASI-II and Digit-Symbol 
The WASI-II IQ scale, and WAIS-III digit-symbol test both came with a 
physical manual including instruction on how to score performance and 
interpret the score. The WASI-II scores were a result of the 2-test version of 
the WASI-II. Only the Matrix Reasoning and Vocabulary Tests were used to 
measure IQ. 
The Raw score for the digit-symbol test is the total number of correct 
symbols matched in the corresponding boxes. Raw scores were converted 
to standardized scaled scores (according to age ranges) using the relevant 
designated table for this conversion in the WAIS-II manual included in the 
battery. 
2.1.2 CUPIT 
The CUPIT came with an attached document as shown in Appendix F which 
highlighted the scoring procedure. Question 2 was used to screen for most 
recent cannabis use (past 3 months) and question 1 screening cannabis 
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use in the past year. A cumulative score of 12 or higher was considered an 
indicator of cannabis-induced problems (Bashford et al., 2010).  
2.1.3. CAST 
The CAST has a maximum score of 6, as each question is scored either 1 
point or 0, and the sum of points from each question gives us the score for 
this test. A score of two cautions the user to be careful of their cannabis use, 
and a score of 3 or higher indicated problematic use of cannabis. This 
measure was used mostly to affirm CUPIT scores, and the scores were not 
used in further statistical analyses. 
2.1.4. SPSES 
The SPSES rating sub-psychotic experiences did not include scoring 
information in the manual, and the information was not made readily 
available. Therefore an overall sum of scores for each question was used 
as would be done with any other ordinary Likert-scale questionnaire. 
Scoring on the Likert scale had the following ratings for the experiences: 0- 
Never happens; 1-Happens, Less than once a month; 2- Several times a 
month; 3- Several times a week; 4- Happens almost every day.  
3. Procedure 
Participants expressing interest in participating in the research 
scheduled a booking with the researcher to come in for the research session 
(see Appendix A). The sessions were approximately 35-45 minutes long. 
This was all done within the controlled environment of one of the 
laboratories in the Applied Cognitive Psychology laboratories. The room 
was ‘office-type’ with a computer for the electronic components of the study, 
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and separate desk with two chairs, on opposite sides, for the WASI-II 
administration. 
The session started with the researcher briefly explaining the research and 
giving the participant an information sheet (see Appendix B) to read before 
starting the session. Following this, the participant was then required to sign 
two consent forms (see Appendix C), one to give back to the researcher and 
the other for the participant to keep. Once they had signed the consent 
forms, the next step was the completing the two subtests of the WASI-II 
required to determine the FSIQ-2. Then the participant proceeded to do the 
digit-symbol Coding test. Once they were done with this, Google’s “generate 
a random number” was used to generate two 3-diggited numbers. The two 
numbers were separated by a forward slash to become the participant’s 
number for the next section of the research. The number was also written 
on the scoring sheets for the WASI-II and the digit-symbol tests.  
The participant then proceeded to complete the online portion consisting of 
a series of questionnaires. The questionnaires included the demographics 
information and some background history (see Appendix D), screening for 
cannabis use (see Appendices E and G), and the sub-psychosis scale (see 
Appendix I). Only those who reported cannabis use were presented with the 
CUPIT and CAST questionnaires. 
Whilst the participant completed these questionnaires on the computer, the 
researcher was scoring their WASI-II and digit-Symbol performance to 
obtain raw scores. This was done within the room, on the desk used for the 
WASI-II test, back towards the participant’s back to reassure the participant 
that their responses were completely anonymous. At the end of each day 
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that participants came in, their raw scores were converted into scaled 
scores (for the digit-Symbol test) and final Full Scale IQ 2-test (FSIQ-2) for 
their performance on the WASI-II. This was also done within the same 
laboratory, to avoid any materials being misplaced (i.e., the tests and the 
transcripts). 
4. Statistical Analysis 
The three outcome variables of the study were WAIS-II IQ scores, 
performance on the digit-symbol test, and overall scores on the Sub-
Psychotic Subjective Experiences Scale (SPSES). All analyses were done 
using IBM SPSS Statistics Version 23. Initially the SPSES was analysed for 
validity and reliability on the basis that no further psychometric information 
was available on the scale. Internal validity was done using a Pearson’s 
correlation for each of the 21 items in the scale. There was no significant 
correlation between Question item 18 and the overall SPSES scores (r=.22, 
n=52, p=.118). This item was removed from the scale, consequently 
disqualified from the total score. 
The SPSES was assessed for reliability as a scale, and found to be reliable 
(good Cronbach’s Alpha value, α=.89); robust (wide range of scores 
indicating varying aspects of psychosis were measured: range=2-58); and 
sensitive (good test to detect positives because there was a wide variance 
in the total scores, SD=14.25).  
Following this, cannabis use was ranked into four groups using CUPIT 
scores for “Question 1” measuring cannabis use in the past 12 months. This 
was used to identify any outliers in the scores of the groups using IBM SPSS 
Boxplots. The groups were: 1-‘Non-user’ group with participants that had 
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never used cannabis (n= 15); 2-‘Previous user’ group with participants that 
had not used cannabis for 12 months and longer (n= 9); 3- ‘Non-regular’ 
user group with participants scoring 5 and below on “Question 1” (n= 13); 
and 4-‘Regular’ were participants ranking 6 and above for “Question 1” (n= 
15). Score of 5 and below indicated cannabis use averaging an estimate of 
2 days a week or less. Scores from 6 upwards indicated cannabis use 
estimates of 3-4 days a week or more. 
One non-regular cannabis user used other recreational drugs more 
frequently than cannabis use, thus this case was removed from the 
analyses in the results. Other recreational drug users used the other drugs 
less than once a month, and these cases were retained because their other 
drug use was marginal. 
The digit-symbol boxplot indicated a single outlier for the digit-symbol 
performance score; a ‘non-regular user’ with a scaled score of 15. FSIQ-2 
boxplot revealed three outliers. A non-user with the FSIQ-2 estimate of 140, 
regular cannabis user with a FSIQ-2 estimate of 144, and a previous 
cannabis user with the estimate FSIQ-2 of 88. SPSES boxplot reflected two 
outliers from the four groups, one regular user with the overall SPSES score 
of 79 (the highest score), and a previous user with an overall of 54. 
Contrastingly, when the data were categorised into two groups: ‘users’ (n= 
29) and ‘non-users’ (n= 23) only two outliers were revealed from all the 
boxplots. These outliers were the FSIQ-2 scores of 140, and 144, and no 
other outliers emerged. 
Once the outliers of the data were revealed, the next step was plotting 
scatter plots and distribution graphs to evaluate the distribution of the 
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different variables being assessed. This was to affirm linearity, normal 
distributions, along with other necessary assumptions relevant for further 
analysis of the data. The digit-symbol and FSIQ-2 data had normal 
distributions. The SPSES scores reflected a positive skew, which could be 
traced to the SPSES scores in the ‘previous users’ (n=9) group, and the 
‘regular users’ (n=15) group. The most distinctive difference is reflected in 
the extremely low scores of the ‘previous’ users group’. This group had the 
lowest range 25-38 (excluding the outlier score of 54). The other irregularity 
was in the ‘regular users’ group with the highest range from 26 to 79, with 
the 4th quartile ranging from 50 to 79. 
Given that the sample population was gathered at convenience primarily 
from a pool of students, the data should closely represent what one would 
find in a similarly characterized sample. For this reason all outliers were 
included in further analyses, as the outliers were very unlikely to be an error. 
The extreme scores of the particular outlier cases may reflect other extreme 
scores on the other measures which could likely reveal some relationship.  
The primary focus of the study is to identify relationships between variables, 
if any; thus all cases were considered important to avoid bias in the findings. 
Given the inclusion of outliers, the analyses reported in the remainder of this 
report were bootstrapped on IBM SPSS. The bootstrapping conditions were 
bias corrected accelerated (BCa) confidence intervals in simple bootstrap 
samples of 1000.  The confidence intervals for all the analyses was 95%.  
Two-tailed tests of significance were used for all correlations. Pearson’s 
correlation coefficient was used for all ratio and interval variables, and 
Spearman’s Rank-Order correlations were conducted for correlations 
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including nominal (categorical) variables. Correlations of cannabis use 
indicators along with correlations for main variables in the study were 
conducted. 
Chi-square analysis was used to affirm the strength of the association 
between the cannabis use, and the use of other drugs. 
A series of one-way analyses of variance (ANOVA) were conducted on 
SPSES scores, IQ scores, and digit-symbol scores within the four groups 
(i.e., the cannabis use groups as independent variable) to detect any 
significant differences in means. 
A one-way (4 cannabis use groups) Multivariate Analysis of Covariance 
(MANCOVA) was conducted to determine the relationship of cannabis use 
on digit-symbol scores and SPSES scores with the recorded possible 
confound variables as the covariates. These included the use of other drugs, 
IQ, and depression. Pillai’s Trace test statistic was used to interpret the 
output results of this analysis (Field, 2009) 




The results of the study include a sample population of 51 (n=51) on 
account of the invalid case that was removed from the original gathered 
sample of 52. This results section will outline what was found regarding the 
relationships between the variables and taking into account possible 
confounding variables. 
1. Descriptive summary of Results of Variables 
1.1. Sub-Psychotic Subjective Experiences Scale (SPSES) 
Scores 
Previous cannabis users had a mean score significantly lower than the 
means of the other groups and the overall mean for the sample population, 
along with the smallest variance in scores than the other groups (µ= 12.33, 
SD=8.82, s²= 77.75). Regular cannabis users presented the highest mean 
and variance of scores within the group (µ= 22.53, SD=16.62, s²= 276.27). 
The differences in means between the four groups in this variable were not 
statistically significant. This was found in the results of the one-way analysis 
of variance (ANOVA) of cannabis use on SPSES scores (F (3, 47) = 1.23, 
p=.31). 
1.2. WASI-II FSIQ-2 Scores 
WASI-II IQ scores presented high variability, and the overall mean was 
comparable with the average IQ range within the general adult population 
of 70-110 (M= 109.55, SD=11.29, s²= 127.53). Nine participants obtained 
IQ scores above 120 indicating superior performance on the scales, and 2 
participants scored above 130, which is likely to indicate intellectual 
giftedness. The lowest IQ score was 88, which still falls into the average 
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range of the general population of 70-130 (Wechsler, 2011). Ergo, no 
underlying cases of learning disability or inappropriate level of 
understanding of the scale were revealed in the IQ results.  
The group with the highest mean of IQ scores was the non-cannabis users 
with a high variance of scores within the group (µ= 111.87, SD=11.02, s²= 
121.55) and previous users obtained the lowest mean of IQ scores (µ= 
106.22, SD=9.79, s²= 95.94). Non regular users had the lowest variability in 
the scores within the group (µ= 111.67, SD= 8.59, s²= 73.88), with regular 
users indicating the highest variance in scores within the group (µ= 107.53, 
SD=14.14, s²= 199.98).  Table 2 outlines descriptive statistics within each 
group for measured variables. 
The differences in overall IQ score means within the four groups were not 
statistically significant, as shown in the results of one-way analysis of 
variance (ANOVA) between IQ and cannabis use (F (3,47)= .760, p=.52). 
When outliers were excluded, the regular users obtained lowest mean of IQ 
scores and still maintaining highest variance (µ= 104.93, SD=10.28, s²= 
105.76) 
1.3. Digit-Symbol Coding Test Scores 
The variability of overall scores for the digit-symbol was not as radical as 
the other two variables, although there was notable variance in the scores 
(M= 10.29, SD=2.27, s²= 5.17). The means and variance of scores within 
each group were sufficiently analogous. The lowest group performance was 
that of the regular users (µ= 10.2, SD= 2.31, s²= 5.31), and the highest 
scoring group were the non-regular cannabis users (µ= 10.42, SD=2.23, s²= 
4.99). Table 2 summarises the details. 
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The differences in means between the four groups in this variable were not 
statistically significant, as shown in the results of one-way analysis of 
variance (ANOVA) between digit-symbol scores and cannabis use (F 
(3,47)= .02, p=.996). 
Table 2.  
Overall descriptive statistics for relevant variables 
Note: SD= standard deviation; s²= variance 
1.4. Cannabis use 
All cannabis users reported having used primarily Marijuana, and 8 of the 
regular users also used other forms of cannabis (see abis used among 
cannabis users  
Table 3). There was one regular user that reported using Hashish, and 2 
non-regular users reported using Hashish. 
Cannabis Abuse Screening Test (CAST) and Cannabis Use Problem 
Identification Test (CUPIT) scores were used to corroborate self-reports of 
cannabis use.  
Overall, there were 36 participants that had used cannabis at least once in 
their lifetime. Current cannabis users included 27 participants out of the 
sample of 51. There were 15 regular cannabis users, and 12 non-regular 
users. 15 participants of the sample population had never used cannabis in 

































their lifetime, and 9 out of the sample population had not used cannabis in 
over at least 12 months. abis used among cannabis users  
Table 3 outlines types of cannabis used among cannabis users  
Table 3.  
Types of Cannabis used in the different groups 





















Note: ‘Other’ not specified 
1.4.1. Cannabis-use indicators 
Cannabis use groups indicated a strong and positive relationship with 
CUPIT scores (rˢ (34) =.831, p=.00). as CUPIT scores were higher, they 
indicated a higher ranking in cannabis use categories Cannabis use and 
CAST scores indicated a positive and moderate to strong relationship, as 
CAST scores were higher, they indicated a higher ranking in cannabis use 
categories (rˢ (34) =.507, p=.002). 
The verifying scores of the CAST on CUPIT scores showed a significant 
positive Pearson’s correlation, thus indicating a strong positive relationship 
between CAST and CUPIT scores (r (34) =.792, p=.00). The higher the 
CUPIT score, the higher the CAST score would be, which validates the 
CAST as successfully corroborating cannabis use ranking and CUPIT 
scores. These correlations were measured to verify true reports on cannabis 




Table 4.  
Bivariate correlations of cannabis use indicators 






















Note: ‘Cannabis’= the cannabis use categories (i.e. Non-user, Previous 
user, Non-regular user, Regular user); *p< .05; **p< .01; ***p<.001 
Overall, CUPIT scores of 12 or above indicated a possibility of Cannabis-
induced problems (Bashford et al., 2010). The overall mean CUPIT score 
for cannabis users indicated an expected general cannabis-induced 
problems within the sample population (M= 16.47, SD=12.8, s²= 163.86). 
Evidently the regular users had a higher mean, however, they also indicated 
more variability in scores (µ= 29.07 SD=8.28, s²=68.49) compared to non-
regular cannabis users (µ= 8.83, SD=5.39, s²= 29.06). As could be expected, 
the mean for non-regular users was below 12 with a lower variability in 





Table 5.  
Descriptive statistics for variables in separate groups 
 





































































































Figure 1.  
Cannabis use on overall SPSES and digit-symbol scores 
 
Figure 2.  
Cannabis Use on overall IQ  
 






































1.1. Other Possible Confounds  
Three possible confounds that were likely to influence digit-symbol 
performance were recorded and taken into account. The 3 variables were 
IQ scores, the use of other drugs, and depression and bipolar; conditions 
that the literature indicated should impact digit-symbol performance. Ten 
participants used other recreational drugs, and they were all current 
cannabis users too. Table 6. below summarises the details of mental health 
diagnoses and use of other recreational drugs within each comparative 
group. 
Table 6.  























Total 3 4 10 14 31 
Note: ‘Other drugs’ not specified 
2. Correlations 
Spearman’s Rank-Order Correlations were used for correlations 
including ‘cannabis use, ‘depression’, ‘other drugs’, and ‘FSIQ’ (because of 
IQ outliers) variables. Pearson’s correlations were conducted for other 





Table 7 summarises the correlation results for each of the main variables in 
the study. No statistically significant relationships were found between any 
of the variables.  
 
 
Table 7.  
Bivariate correlations of main variables 








































Note: ‘Cannabis’= the cannabis use groups (i.e. Non-users, Previous 
users, Non-regular users, Regular users). 
2.1. Other Possible Confounds 
There was a moderate and negative relationship between cannabis use, 
and the use of other drugs (rˢ (49) = -.438, p= .001). Responses to ‘Other 
Drug use’ question were coded as follows: “1=yes” and “2=no”. Thus, those 
in group 1 (yes) ranked higher in cannabis use, and those in group 2 (no) 
ranked lower in cannabis use. The Chi-square test affirms the statistically 
significant association between cannabis use and the use of other drugs (χ² 
(3) = 11.24, p= .01) 
3. Multivariate Analysis of Covariance (MANCOVA) 
An overall one-way (4 Cannabis use groups) MANCOVA was performed on 
digit-symbol scores and SPSES scores with the use of other drugs, IQ, and 
depression as covariates. Pillai’s trace indicated no significant effect of 
cannabis use on digit-symbol performance and SPSES scores V= .09, F (6, 
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88) = .68, p= .66. None of the covariates indicated a significant effect over 
the variables in this analysis. 
The next section is the discussion section which will discuss the results 




The results showed no statistically significant evidence to support the 
hypotheses that: 1) regular cannabis users would have higher ratings of 
sub-clinical psychotic experiences; and 2) the use of cannabis would result 
in lower digit-symbol scores, thus regular users obtaining among the lowest 
scores in the sample population. The results showed no significant 
relationships were found between the three variables. Furthermore there 
were no statistically significant differences in means for each of the core 
variables of measure (digit-symbol performance, SPSES scores, and IQ 
scores) within the four groups (cannabis use). This indicated that cannabis 
use did not significantly influence the measures of IQ, SPSES scores, and 
digit-symbol performance. None of the expected confounds had a significant 
effect on the main variables of the study.  
1. Cannabis Use 
Twenty out of the 51 participants were current users of cannabis (52.94%), 
and the extent of their cannabis use was compared in two measures. This 
was to confirm the reports on one measure would correspond with the 
results of the other measure to affirm extent of cannabis use. CAST scores 
successfully correlated with CUPIT scores, thus confirming the extent of 
cannabis use within the sample population. The majority of these 
participants were students, and although the high CUPIT and CAST scores 
suggested problematic levels of use, it was interesting to find that the 
cannabis use did not impact their performances on the other measures in 
the study. 
This study only accounted for typical strains of cannabis stemming from 
natural forms of cannabis. These were marijuana, cannabis oil, hashish, and 
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other types reported were edible (cooked into foods) forms of the natural 
strains. However, the recent reports in New Zealand media regarding 
increasing cases of synthetic strains of cannabis would likely impact the 
results of this study if any participants were either knowingly or unknowingly 
using synthetic strains. The reports in the media seemed to suggest that 
individuals using the drug were able to distinguish natural from synthetic. It 
is probable that participants would have reported the use in synthetic 
cannabis in the ‘other’ section asking about types of cannabis used, or in 
the section asking about the use of other recreational drugs. Participants 
only reported use of the aforementioned natural types of cannabis. 
2. SPSES findings 
The SPSES questions were used to assess sub-psychotic 
experiences that may exist undetected. This scale was to reveal whether 
regular users would indeed report higher ranking of sub-psychotic 
‘symptoms’ than the other groups.  This was indeed the case, with regular 
users obtaining the highest mean of 22.53; however the difference was not 
on a significant level as non-user ratings followed immediately with a mean 
of 22.33. 
In order to avoid bias in self-ratings of the SPSES, words closely linked 
with/related to the word “psychosis/ psychotic” were avoided, and the word 
‘perception’ used in replacement. The participants were told that this scale 
was to assess their subjective experiences on a day-today basis.  
There was no chronological order of SPSES score in accordance with level 
of cannabis use. The results of the correlation analysis of SPSES overall 
scores and cannabis use indicated no relationship between the variables. 
Correspondingly, SPSES scores indicated no effect as a predictor variable 
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in the analyses of variance. These findings contradict the hypothesis of a 
positive relationship between cannabis use and SPSES scores. Accordingly, 
regular cannabis users did not present the significantly higher ratings of sub-
psychotic experiences hypothesised. 
Three of the four groups presented comparable distributions in their overall 
SPSES ratings, and respectively close results to the overall statistics of the 
sample population.  
It is critical to note the particularly extremely low SPSES self-ratings of the 
‘Previous users’ group. The group did comprise of the smallest number, and 
their scores all ranged below the mean except for the outlier. This particular 
group scored exceptionally low, and had the lowest variance in ratings; and 
this may have been on account of varying reasons. 
This segment of the study (the SPSES questionnaire) raised the most 
queries among participants. Numerous participants seemed to find the 
questions either too lengthy or difficult to understand. This may have 
created the unexpected bias in their answers, consequently the rampant 
variance in scores. Comprehension of the questions may have been 
especially more difficult for the older population because of the choice of 
wording. The majority of the ‘previous users’ group comprised of the older 
participants of the study; this may have been an influencing factor on the 
ratings of the scale. The other aspect worth note is that the questions 
appeared in a very small text, were very lengthy, and presented as the last 
item of the session. This may possibly have made the questions more 
difficult to read along with participants eager to complete the session.  
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The feedback from participants after the sessions all seemed to suggest 
that the last measure was slightly more complex to comprehend and/or 
complete. The wording of questions (complexity) along with text size may 
have contributed to the extreme variance in participant ratings. 
The ‘regular cannabis users’ presented scores with the highest variance 
than any other scores measured in the study. The fact that this scale is a 
self-report scale may have, to some degree, also resulted in some bias. 
3. Depression  
There should have been a relationship between depression and digit-
symbol performance as indicated in varying literature. Participants with 
depression were anticipated to perform significantly poorer on both the digit-
symbol test, and achieve lower IQ scores. This was the reason this item was 
measured as a confounding factor in the study, and included in the analysis 
of the results. There was no statistically significant effect of depression on 
any of the other variables. The sample size of those with depression was 9 
out of the 51 sample population, thus a relatively small number. An element 
relevant to this is that the participants had been reporting a diagnosis of the 
disorder; therefore most likely receiving treatment for their depression. This 
may be the reason why no notable relationship was found between 
depression and any of the other variables of the study. 
4. IQ 
IQ was measured in this study because this item would most likely 
impact individual performance on the digit-symbol, along with prospect of 
comprehending the other measures. There were two very high IQ scores, 
possibly indicating intellectual giftedness. These two scores were included 
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in the results, because they were representative of a sample population with 
similar characteristics. All other IQ scores fell within the average IQ of the 
larger population ranging within 70-130. This was to be expected given that 
majority of the participants were tertiary level students. There were no 
statistically significant relationships between IQ scores and any of the other 
variables. This means that IQ had no significant correlation with scores on 
digit-symbol test, and SPSES.  
Overall in the literature, IQ scores of patients with psychosis were 
inferior to those of the ‘healthy’ controls (Leeson et al., 2008; Mohamed et 
al., 1999). Patients with psychosis were found to perform poorer on the 
subtests relying more heavily on working and verbal memory (Leeson et al., 
2008) and information processing (Dickinson et al., 2007). Thus it was 
expected that those ranking higher on the SPSES scale would most likely 
obtain lower IQ scores, and lower IQ would correlate with cannabis use 
(inferred from the hypothetical notion that cannabis use would correlate with 
SPSES). However, this was not the case, the group with the lowest IQ 
scores were previous cannabis users, and this group also scored the lowest 
ratings on the SPSES. 
On the other hand, the next lowest IQ group mean was the ‘regular 
cannabis user’ group, and this mean was only 1 score higher than the 
‘previous user’ group. This mean included the highest IQ score in the study, 
as the individual fell into this group. This entailed that the mean for this group 
was significantly more elevated than what it would have been without this 
outlier. With the exclusion of the outlier, the regular cannabis user group 
would have achieved the lowest IQ, and this would correlate with what is 
suggested in the literature. This group also had the highest mean for SPSES 
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ratings, consequently coinciding with what would be expected. Increase in 
SPSES scores was expected to result in decline in IQ scores. The ultimate 
implication is that the ‘regular cannabis user’ group would achieve the 
lowest IQ (without the outlier case) and the highest SPSES scores. This is 
only on a surface level inspection of results, analysis revealed no significant 
relationships. Ultimately, there was no significant effect of IQ on any of the 
other variables. Consequently, results revealed that IQ was not a significant 
confounding variable of the study, and did not disturb the results of the other 
measures. The exclusion of the outlier case would be a misrepresentation 
of the sample population, and would reduce the authenticity of the degree 
to which the sample population represents a similarly characterised 
population. 
5. Digit-symbol 
The hypothesis that there would be a negative correlation between 
cannabis use and digit-symbol performances was not confirmed by the 
results of this study. The proposed notion was that regular cannabis users 
would perform poorer on the digit-symbol. The statistics indicated a 
negligible relationship between cannabis use and digit-symbol performance. 
Both correlations between cannabis use on digit-symbol scores, and CUPIT 
scores on digit-symbol scores presented insignificant relationships. The 
CUPIT scores measured extent of cannabis use, and no correlation 
between CUPIT scores and digit-symbol performance indicated that the 
extent of cannabis use among users did not correlate with their performance 
on the digit-symbol test. 
SPSES results were also compared with digit-symbol results to determine 
whether or not there would be a negative relationship. There was no 
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significant correlation between SPSES scores and digit-symbol 
performance. This suggests that experiences of psychosis do not produce 
a significant correlation with digit-symbol performance. 
The digit-symbol test primarily measures working memory, processing 
speed and visuo-spatial memory. Psychosis is described as a range of 
unusual experiences that can affect a person’s thoughts, feelings and 
experiences. Experiences of psychosis usually affect the cognitive domains 
measured by the digit-symbol test, thus there should have been a 
relationship present between SPSES ratings and individual’s performances 
on the digit-symbol test. The absence of such a relationship brings to 
question whether the SPSES scale in fact measured experiences 
associated with underlying psychotic symptoms, or whether the scale was 
in fact a robust measure including all the features of psychosis. Although 
the measure is not a diagnostic tool, and only functioned to measure 
subjective experiences, if the subjective experiences were indeed 
associated with symptoms of psychosis then there should have been a 
statistically significant relationship between the variables. The questions of 
the SPSES though outlining some features of sub-psychotic experiences 
may have failed as a predictor tool of sub-psychotic experiences. Though 
the reliability and internal validity of the SPSES were tested and confirmed, 
perhaps the construct validity of the questions could be further investigated. 
Co-occurrence of cannabis use and other recreational drugs. 10 out of 27 
(37.03%) of current cannabis users were using other recreational drugs. 
This included 6 out of 15 regular users (40%), and 4 out of 12 non-regular 
users (33.33%). These are large portions of the cannabis users that were 
currently using other recreational drugs, some would be using multiple other 
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recreational drugs too. Although the frequency of use of other recreational 
drugs was low, this variable could have majorly influenced the results of the 
study. This is especially the case for the use of other drugs more potent 
than cannabis. 
6. Limitations and further directions 
6.1 Sample 
Overall, though 51 participants were sufficient at this level for statistical 
significance within a ‘clinical population’ this number may not have been 
enough to bring about a sufficient representation of all the variables in the 
study. Predominantly important to note was that the variables were 
compared in groups of four, which further decreased the sample statistic in 
each group. The analyses looking at relationships within the four groups 
were done on relatively small numbers, and would make the findings less 
generalizable to the larger population. A larger sample population would be 
beneficial for future study similar to this one. Otherwise a smaller division of 
the already collected number (e.g., into three groups instead of four). 
Paired Sampling may have been very useful to avoid the very radical results 
within the variables. For example if participants were matched according to 
IQ, age, and gender, then it would have reduced the number of major 
differences between individual samples. Although the participant sample of 
convenience was selected to provide a more adequate representation of 
what would be more likely to be found in a similarly characterized population. 
The random representations within the sample may have led to the drastic 
variability in results, however, this also provided a more authentic 





A review of the chosen materials and measures of the study. 
6.2.1 SPSES 
It became apparent that the use of the SPSES to indicate underlying sub-
clinical experiences could be improved in future studies. This measure 
proved to be somewhat wordy and not very user friendly for the participants 
(too complex). Another thing to consider is that although the test appeared 
to be testing the same thing and produced reliable scores, whether or not 
the scale was in fact measuring sub-psychotic experiences in a vigorous 
custom could not be confirmed. It seems the questions were primarily 
focused on issues pertaining to attention as opposed to an array of 
experiences involved in psychosis, even on a sub-clinical level. It might be 
useful to replace the use of the SPSES measure in future studies, however 
it may be difficult to find other similar measures which are not diagnostic. 
The primary reason for using the questions in this scale was to avoid 
diagnosis, and just to assess subjective perceptions of individuals. However, 
whether or not these experiences correlated with psychosis (one of the main 
factors of investigation in the study) was unconfirmed. A problem regarding 
the SPSES was that very little to no other information about the measure 
was available. 
 
This is not to completely nullify the results of the SPSES results, because 
ultimately the scores were found to be reliable and valid, thus indicating a 
measure of some particular feature (perhaps attention). The scores on this 
scale did ultimately indicate problems in subjective perceptions; however, 
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the questionnaire items may not have fully covered all the features defining 
psychosis. 
Given that obtaining better scales to measure sub-clinical psychotic 
experiences were a challenge, it might be worth looking into devising a scale 
for such a measure; one that is not diagnostic and practical for research 
purposes. 
6.2.2. Cannabis Use  
The use of the CUPIT and CAST score to corroborate self-ratings of 
cannabis use proved the most successful element in the study. The CUPIT 
was not only very useful in identifying frequency of cannabis use among 
users, it was also very useful in measuring extent of cannabis use. The 
CAST scores effectively estimated the extent of cannabis use too, thus 
producing a strong positive relationship between CUPIT and CAST scores. 
 
An important factor that was neglected in the results of this study was age. 
The literature regularly mentioned the age at which an individual began 
using cannabis as an important predictor variable in terms of developing 
psychosis. Age was poorly recorded in this study, particularly the timeframe 
in which individuals had been using cannabis. The number of years, and 
starting age of cannabis use are important variables that were neglected in 
this study. These are important variables to factor into future research 
endeavours along the same stream as this study. Age and years of 
cannabis use are more likely to have been better predicator variables of 
psychosis than most of the other variables measured in this study.  
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6.2.3. IQ & Digit-Symbol 
The decision to use the 2-test version of the WASI-II may have reflected 
more accurate IQ estimates with the inclusion of the other 2 subtests. This 
would have given more rigorous results, although IQ testing was not a 
primary goal in the study. However, after testing the first few participants it 
became apparent that there would have in fact been enough time to 
complete all four subtests of the WASI-II. This would have also allowed 
more results to compare in the analysis. The only reason the Matrix 
Reasoning and Vocabulary subtest results were not mentioned in the results 
of this study is because they yielded no statistically significant relationships. 
The inclusion of their analyses against the other variables would have been 
futile, given that the study was not focused on these measures. 
In a future study it might be possible that all subtest may be useful and there 
might be significant correlations between the subtests and other variables 
within the study.  
The other thing is that radically inclined results on the IQ scale may have 
occurred on account of the fact that only two subtests were used to measure 
IQ. These tests may have presented the best or worse indices within the 
individual. 
Only one part of the digit-symbol test was used, the coding part. This was 
because the literature tended towards deficiencies in the coding process of 
the digit-symbol test (primarily processing speed). It would be interesting to 
look into how individuals would perform on the incidental recall component 
of the test. This component measures how many of the symbols are 
remembered immediately after completing the coding task. This task is 
more focused on the working memory aspect of the digit-symbol scale. 
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Including this measurement in the study, the study might have had 






The primary objective of this study was to assess performance on digit-
symbol performance alongside self- reports of cannabis use, and self-
reports of sub-psychotic experiences (distorted perception) for any 
correlations.  
Sub-psychotic experiences were measured to identify whether regular 
cannabis use would result in higher ratings, thus demonstrating undetected 
experiences of psychosis within the general population of cannabis users. 
No significant relationship was found, thus suggesting that regular cannabis 
users in the general population do not ordinarily experience sub-psychotic 
experiences that are undetected. 
The assumption was that higher ratings of sub-psychotic experiences would 
result in lower scores on both full-scale IQ and digit-symbol performance, 
and vice versa. However, no significant relationships were found in this 
study to support these notions. There were no relationships found to support 
the notion that regular cannabis us would diminish digit-symbol performance 
indicating impairment in working memory and processing speed. This task, 
particularly the coding part of the test, was proven to be difficult among 
individuals with psychosis. The theory was that if regular cannabis users 
displayed symptoms of psychosis, they would correspondingly perform 
poorer in the digit-symbol test. This study did not produce results to support 
this notion, thus supporting the null hypothesis of the study.  
All the measured variable that were expected to present strong influence 
(confounding variables) over the research variables did not present any 
significant relationships with the research variables. Thus no confounds 
were identified from the analysis. 
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A significant relationship was found between cannabis use and the use of 
other recreational drugs. Although the frequency of the other drugs all 
ranged below a frequency of once a month, the potency of the other drugs 
in comparison to cannabis varied. Past drug history was not accounted for 
either, only current use. An implication of this would be that lasting effects 
on cognition from these other drugs could have presented a bias in the 
results of the study. The use of other drugs did not, however, present a 
significant relationship with the other variables in the study. The 
measurement of other drug use was not very intricate, as this was not the 
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Appendix B: Participant Information Sheet 
Cannabis use on Digit-Symbol Performance and Perception 
Participant Information Sheet 
This study aims to investigate the relationships between cannabis use, cognitive 
experiences, and performance on the Digit Symbol Test. The Digit Symbol test is 
one of the tasks used in cognitive psychology for measuring processing speed, 
and working memory. 
What is requested of the participant? 
1) Read through and sign TWO consent forms 
2) Approx. 25-30 mins for two cognitive tests: WASI Vocabulary subtest, and 
WASI Matrix Reasoning subtest. Both of these tests are verbal tests and 
no writing is required. You will be asked questions which you will respond 
to verbally whilst the researcher records them 
3)  Approx. 3-5 mins Digit-Symbol task. For this task, you are requested to 
match symbols with their corresponding digits within 120seconds. You 
will be required to write for this exercise and all materials (pencil and 
paper) will be supplied. 
4) We will then move on to the computer for the second part of the session. 
We will generate a random participant number for you to quote on your 
questionnaire and to write on the tests we have just completed. 
5) After this, you are requested to complete approx. 10-15 minute 
electronic questionnaire. This is completely anonymous, and you may 
request for the researcher to leave at this time. 
The overall estimated time for the session should be approx. 40-50 mins. 
Your participation is greatly appreciated. All information is confidential and 
anonymous and participants have the right to withdraw at any time. 
Any further queries or information that you may require regarding the research, 
kindly contact the primary researcher (Wabuya Vaka) at psychcannabis@gmail.com. 
If you have any concerns regarding the research you are welcome to contact 
Wabuya or her supervisor Dr Robert Isler at robert.isler@waikato.ac.nz  
If you feel unsettled because of the content of this study and require further 
support or professional help, you are kindly encouraged to call the free Waikato 
crisis line on 0800505050, which is in operation 24/7. Alternatively, if you are a 
student at the university you may reach the student counselling service at 
counselling@waikato.ac.nz or on +64 838 4037 
The Research protocols for this research have been reviewed and approved by 







Appendix C: Participant Consent Form 
CONSENT FORM 
A completed copy of this form should be retained by both the researcher and the 
participant.  
Research Project:  Cannabis Use on Digit Symbol Test and Perception _ 
Please complete the following checklist.  Tick () the appropriate box for each 
point.  
YES NO 
1. I have read the Participant Information Sheet (or it has been read to me) 
and I understand it.   
  
2. I have been given sufficient time to consider whether or not to participate in 
this study 
  
3. I am satisfied with the answers I have been given regarding the study and I 
have a copy of this consent form and information sheet 
  
4. I understand that taking part in this study is voluntary (my choice) and that I 
may withdraw from the study at any time without penalty 
  
5. I have the right to decline to participate in any part of the research activity 
during or before the session 
  
6. I know who to contact if I have any questions about the study in general.   
7. Due to the sensitive nature of this research I may feel unsettled, and I know 
who to contact or where to go if this happens 
  
8. I understand that I may have to disclose some personal illicit information    
9. I understand that no legal harm will come from my sharing illicit information 
in this study 
  
10. I understand that my participation in this study is confidential and that no 
material, which could identify me personally, will be used in any reports on 
this study. 
  
11. I wish to receive a copy of the findings   
If you answered YES to question 11, please provide email address: 
12. I consent to the information gathered during my participation session being 
used in this research 
  
Declaration by participant: 
I agree to participate in this research project and I understand that I may withdraw at any 
time. If I have any concerns about this project, I may contact the convenor of the Psychology 
Research and Ethics Committee (Dr Rebecca Sargisson, phone 07 557 8673, email: 
rebecca.sargisson@waikato.ac.nz)  
Participant’s name (Please print): 
Signature: Date: 
Declaration by member of research team: 
I have given a verbal explanation of the research project to the participant, and have 
answered the participant’s questions about it. I believe that the participant understands the 
study and has given informed consent to participate. 




Appendix D: Online Questionnaire Demographics 
Introduction: Hello and thank you for volunteering to participate in my research. 
Up next is a questionnaire which should take no longer than 20 minutes. This is 
the final activity to complete your participation. The information from this survey 
will be used for research purposes only. By clicking next you agree to participate 
in this survey. Please answer ALL the questions you are presented with as 
truthfully as you can. Your answers will be held strictly confidential and 
anonymous.  





 18 - 24 
 25 - 34 
 35 - 44 
 45 - 54 
 55 - 64 
 65 - 74 
 75 - 84 
 85 or older 
Q3 Occupation (please select all appropriate boxes): 
 Student 
 Employed part-time 
 Employed full-time 
 Self-employed 
 Unemployed 







 Middle Eastern 
 Indian 
 Latin American 
 African 
 Other ____________________ 
Q5 Are you currently, or have you ever been diagnosed with a mental health 
condition by a professional? (e.g. Learning Disability, Depression, 





Q5.1 Please specify what mental health condition? 
Q5.2 Please specify when this happened? 
Q6  Have you ever suspected you have a mental health condition but never 
sought professional advice? 
 Yes 
 No 
Q6.1 Please specify what mental health condition? 
Q6.2 Please specify when this happened? 
Q7 Have you ever used cannabis (e.g. Marijuana, Hashish, Cannabis oil etc.)? 
 Yes 
 No 
Q7.1 What type of Cannabis? 
 Marijuana 
 Hashish 
 Cannabis oil 
 Other ____________________ 
 
Q7.2 When did you last use cannabis? 
Q7.3 When did you start using cannabis? 
Q8 Do you use any other recreational drugs besides Cannabis? (e.g. LSD, 
Amphetamines, Ecstasy etc.) 
 Yes 
 No 
Q8.1 Please specify type of drug/s 
Q8.2 Please estimate how often you use these? 
 Less than one day a month 
 Once a month 
 2-3 times a month 
 Weekly 
 Twice a week 






Appendix E: Online Cannabis Use Problems Identification Test 
(CUPIT) 
 
Instruction Part One: In this part of the questionnaire you are requested to 
complete all of the below questions regarding your Cannabis use. Answers are 
strictly confidential and anonymous. It is very important to please answer all 
questions as truthfully as you can. For each question tick the answer closest to 
your cannabis use over the time range specified. 
Q1 On how many days have you used cannabis during the past 12 months? (If 
there was no pattern to your cannabis use, please make your best estimate.) 
 1 – 6 days (less than one day a month) 
 7 – 12 days (an average pattern of one day a month) 
 13 – 36 days (an average pattern of 2 – 3 days a month) 
 37 – 52 days (an average pattern of one day a week) 
 53 – 104 days (an average pattern of 2 days a week) 
 up to 208 days (an average pattern of 3-4 days a week) 
 up to 312 days (an average pattern of 5-6 days a week) 
 up to 365 days (daily/most days) 
Q2 Now please think about your recent cannabis use. On how many days have 
you used cannabis over the past 3 months (90 days)? 
 no days 
 1 – 2 days (less than one day a month) 
 3 – 4 days (an average pattern of one day a month) 
 5 – 9 days (an average pattern of 2 – 3 days a month) 
 10 – 15 days (an average pattern of one day a week) 
 16 – 26 days (an average pattern of 2 days a week) 
 27 – 52 days (an average pattern of 3 – 4 days a week) 
 53 – 78 days (an average pattern of 5 – 6 days a week) 
 79 – 90 days (daily/most days) 
 
Instruction: The next section is about over the past 12 months (the past year) 
Q3 How many times would you use cannabis on a typical day when you were 
using? (Note: at least one hour between each new ‘use’)  
 once 
 twice 
 3 – 4 times 
 5 – 6 times 
 7 – 9 times 
 10 or more times 
Q4 How often have you used cannabis first thing in the morning? 
 never 
 once or twice 
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 less than monthly 
 monthly 
 one day a week 
 several days a week 
 daily/always 
Q5 How much of the average day do you spend/or feel stoned? 
 0 hours 
 1 – 2 hours 
 3 – 4 hours 
 5 – 6 hours 
 7 – 8 hours 
 9 or more hours 
Q6 How difficult do you think you would find it to stop using or go without 
cannabis altogether? 
 not at all difficult 
 a bit difficult 
 quite difficult 
 very difficult 
 impossible 
 
Q7 What was the longest time you went without using cannabis? 
 6 months or longer 
 3 – 5 months 
 1 – 2 months 
 2 – 3 weeks 
 one week 
 4 – 6 days 
 2 – 3 days 
 one day 
 no days at all 
Q8 Have you felt that you needed cannabis? 
 never 
 sometimes 
 quite often 
 very often 
 always/all the time 
Q9 Have you been able to stop using cannabis when you wanted to? 
 never/at no time 
 sometimes (not often) 
 quite often (half the time) 
 very often (usually) 
 always/all the time 
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Q10 Have you found it difficult to get through a day without using cannabis? 
 never 
 sometimes 
 quite often 
 very often 
 always/all the time 
Q11 Did your use of cannabis ever interfere with (get in the way of) your work at 
school, your job, or your home life? 
 never 
 sometimes 
 quite often 
 very often 
 always/all the time 
Q12 Have you lacked the energy to get things done in the way you used to? 
 never 
 sometimes 
 quite often 
 very often 
 always/all the time 
 
Q13 Have you given up things you used to enjoy or were important because of 
cannabis? (e.g., work, school, sports, hobbies, being with family and friends, etc.) 
 none at all/nothing 
 one or two things 
 quite a few things 
 lots of things 
 everything 
Q14 Has anything you had planned, or were expected to do, not happened after 
using cannabis?(e.g., a family outing, chores, taking care of children, homework, 




 quite often 
 very often 
 always/all the time 
Q15 Have you had problems concentrating and remembering things? 
 never 
 sometimes 
 quite often 
 very often 
 always/all the time 
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Q16 Did you ever use cannabis after you had decided not to? 
 never 
 sometimes 
 quite often 
 very often 











Appendix G: Cannabis Abuse Screening Tests (CAST) 
 Never Rarely 
From time 
to time 
Fairly Often Very Often 






          
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          
5. Have you 
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          
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Appendix I: Sub-Psychotic Subjective Experiences Scale (SPSES) 
 
We sometimes experience subtle problems in thinking or feeling. We may not 
even notice them or consider them a problem. The following questions ask 
whether you have experienced problems of this type. If you have had these 
problems, we will ask you to indicate when you first started to experience them. 
For each item, select the number that best fits your experience. If you select 1 or 
higher, please select an option on the right side that is closest to when you first 
had that type of experience. If you select 0, do not answer the questions on the 
right just go to the next question. 
1. I feel that doing two things at once is impossible even when I try to 
do the simplest things (like preparing a sandwich while watching 
TV; or other situations where I try to do two simple things at once)  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 




2. I cannot listen to someone and take notes at the same time  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
3. I have difficulties with situations that need divided attention. For 
example, I cannot listen to the radio and drive, or wash dishes and 
talk to others, or other similar difficulties  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 





4. If I don't focus, other thoughts come into my mind. These thoughts 
suddenly appear, but they are not related to what I am actually 
doing  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
5. I sometimes find it difficult to concentrate, because at those times I 
feel every sound distracts me and brings up unrelated thoughts  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
6. I can't help but keep thinking about other things, which is very 
distracting 
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
7. My mind easily goes blank, as if my thoughts disappear whenever 
I start thinking  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
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□ Within the past 1 year 





8. Sometimes my thoughts just stop, or are suddenly gone like being 
cut off  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
9. I often lose my train of thought because other thoughts enter my 
mind  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
10. I cannot think of the right words and have to use other, less 
precise, words 
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
11. My answers are not clear. I ramble somewhat until I find 
something appropriate to say 
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
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0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 





12. I lack the words to express my thoughts and have to search my 
mind for them 
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
13. When I am stressed my mind gets chaotic and I have problems 
thinking straight  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
14. My thoughts sometimes jump from one subject to another so much 
that they are actually not related to each other 
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem 
  
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within:
 
15. I have felt overwhelmed by a great number of thoughts in my head 
at the same time 
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1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 




16. When I am reading something, watching TV, or listening to the 
radio, I have had the experience that there was specific meaning 
there for me. Of course I knew straight away that it was just my 
imagination 
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 




17. Sometimes I have felt that people were looking at me in public 
places or streets, although I knew it wasn't true  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
18. Sometimes when I hear something, like a dog barking, a cat 
meowing, or a noise from cars or appliances, out of the blue I have 
felt they may be occurring because of me, and then I told myself 
that this is nonsense  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  





If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
19. Sometimes an object really seems to stand out from the rest of 
what I see. My eyes then have to fix on it even if I don't want to 
look at it  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
20. A small detail in my surroundings can catch my attention and I 
have to look at it for a while without really wanting to, like I was 
spellbound  
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 
□ Within the past 3 months 
□ Within: 
 
21. A particular feature (for example, something on the wall, or part of 
a person's face or body part) can quickly catch my attention out of 
the blue, and I have to hold my attention on it for a while 
1. Happens. Less than once a 
month; not bothering me  
2. Several times in a month; 
occasionally bothering me  
3. Several times a week; 
bothering me a bit  
4. Happens almost every day; 
really bothering me  
0. Never happens to me, nor a 
problem  
 
If 1 or greater, when did you first 
have this problem? 
□ It’s been a problem for most 
of my life 
□ Within the past 1 year 




Appendix J: Digit-Symbol Coding Subtest 
 
 
